Angiogenesis as a target for cancer therapy


如何引用文章

全文:

详细

The ability of a transformed cell to evolve into the tumor lump is believed to require the secretion of angiogenic factors and active orchestrating of capillary development. Tumor angiogenesis is distinct from the normal one: rapidly growing capillaries lack proper tissue organization and connect to each other in a rather stochastic way, leading to abnormal blood flow and intratumoral oedema. Angiogenic inhibitors selectively destroy immature capillaries and thus normalize tumor vascularization. This results in improved delivery of cytotoxic drugs and sensitization of transformed cells to antitumor treatments. Combined administration of cytotoxic and antiangiogenic drugs improves outcomes of cancer therapies.

作者简介

E Imyanitov

ФГБУ НИИ онкологии им. Н.Н.Петрова Минздрава России, Санкт-Петербург

д-р мед. наук, проф., зав. отд. биологии опухолевого роста

参考

  1. Amit L, Ben-Aharon I, Vidal L et al. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors - a meta - analysis and systematic review. PLoS One 2013; 8 (1): e51780.
  2. Bellou S, Pentheroudakis G, Murphy C, Fotsis T. Anti - angiogenesis in cancer therapy: Hercules and hydra. Cancer Lett. 2013 Sep 28; 338(2): 219-28.
  3. Carmeliet P, Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473 (7347): 298-307.
  4. Cesca M, Bizzaro F, Zucchetti M, Giavazzi R. Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents. Front Oncol 2013; 3: 259.
  5. Chau N.G, Haddad R.I. Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res 20131; 19 (3): 524-9.
  6. Custodio A, Barriuso J, de Castro J et al. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. Cancer Treat Rev 2013; 39 (8): 908-24.
  7. de Gramont A, Van Cutsem E, Schmoll H.J et al. Bevacizumab plus oxaliplatin - based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13 (12): 1225-33.
  8. Di Marco V, De Vita F, Koskinas J et al. Sorafenib: from literature to clinical practice. Ann Oncol 2013; 24 (Suppl. 2): ii30-7.
  9. Dietvorst M.H, Eskens F.A. Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept. Biol Ther 2013; 3: 25-33.
  10. Dutcher J.P. Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol 2013; 5 (6): 338-53.
  11. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133 (2): 275-88.
  12. Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev 2012; 38 (5): 484-93.
  13. Giantonio B.J, Catalano P.J, Meropol N.J et al. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25 (12): 1539-44.
  14. Goel S, Wong A.H, Jain R.K. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med 2012; 2 (3): a006486.
  15. Gross-Goupil M, Fran Нois L, Quivy A, Ravaud A. Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma. Clin Med Insights Oncol 2013; 7: 269-77.
  16. Grothey A, Van Cutsem E, Sobrero A et al. CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo - controlled, phase 3 trial. Lancet 2013; 381 (9863): 303-12.
  17. Heinrich M.C, Maki R.G, Corless C.L et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib - resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26 (33): 5352-9.
  18. Huang Y, Goel S, Duda D.G et al. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013; 73 (10): 2943-8.
  19. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307 (5706): 58-62.
  20. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013; 31 (17): 2205-18.
  21. Joulain F, Proskorovsky I, Allegra C et al. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Br J Cancer 2013; 109 (7): 1735-43.
  22. Kassem M.G, Motiur Rahman A.F, Korashy H.M. Sunitinib malate. Profiles Drug Subst Excip Relat Methodol 2012; 37: 363-88.
  23. Lainakis G, Bamias A. Targeting angiogenesis in renal cell carcinoma. Curr Cancer Drug Targets 2008; 8 (5): 349-58.
  24. Lambrechts D, Lenz H.J, de Haas S et al. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013; 31 (9): 1219-30.
  25. Mitchell E.P. Targeted therapy for metastatic colorectal cancer: role of aflibercept. Clin Colorectal Cancer 2013; 12 (2): 73-85.
  26. Mortimer J, Zonder H.B, Pal S.K. Lessons learned from the bevacizumab experience. Cancer Control 2012; 19 (4): 309-16.
  27. Patel A, Sun W. Zivflibercept in metastatic colorectal cancer. Biologics 2014; 8: 13-25.
  28. Sirohi B, Philip D.S, Shrikhande S.V. Regorafenib: carving a niche in the crowded therapeutic landscape. Expert Rev Anticancer Ther 2013; 13 (4): 385-93.
  29. Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol 2012; 5: 63.
  30. Suspitsin E.N, Kashyap A, Shelekhova K.V et al. Evidence for angiogenesis - independent contribution of VEGFR1 (FLT1) in gastric cancer recurrence. Med Oncol 2013; 30 (3): 644.
  31. Tabernero J, Van Cutsem E, Lakomý R et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014; 50 (2): 320-31.
  32. Takano S. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol 2012; 29 (2): 73-86.
  33. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin - based regimen. J Clin Oncol 2012; 30 (28): 3499-506.
  34. van Geel R.M, Beijnen J.H, Schellens J.H. Concise drug review: pazopanib and axitinib. Oncologist 2012; 17 (8): 1081-9.
  35. Wells S.A Jr, Gosnell J.E, Gagel R.F et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28 (5): 767-72.
  36. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013; 123 (8): 3190-200.

版权所有 © Consilium Medicum, 2014

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##